Therapeutic Effects of a Novel Fusion of Alt-803, an Il-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2b8t2m) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (Bl)
Document Type
Abstract
Publication Date
6-2018
Journal Title
Pediatric Blood & Cancer
Department
Pediatrics
Second Department
Epidemiology and Community Health
Recommended Citation
Chu, Y., Su, N., Alter, S., Jeng, E. K., Rhode, P. R., Barth, M., Lee, D. A., Wong, H. C., & Cairo, M. S. (2018). Therapeutic Effects of a Novel Fusion of Alt-803, an Il-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2b8t2m) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (Bl). Pediatric Blood & Cancer, 65 (Suppl.5), S101. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/223
COinS
